Edgewise Therapeutics (EWTX)
(Delayed Data from NSDQ)
$13.61 USD
-0.70 (-4.89%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $13.60 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Edgewise Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
EWTX 13.61 -0.70(-4.89%)
Will EWTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EWTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EWTX
All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy
Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?
EWTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data
Other News for EWTX
Janus Henderson Global Life Sciences Fund Q2 2025 Commentary
Peloton upgraded, Booking downgraded: Wall Street's top analyst calls
Raymond James Initiates Coverage on Edgewise Therapeutics (EWTX) with Strong Buy
Edgewise Therapeutics initiated with bullish view at Raymond James, here's why
PERCEPTIVE ADVISORS LLC Increases Stake in Praxis Precision Medicines Inc